Prograf News
ASTELLAS TO MOVE DRUG DEVELOPMENT HQ FROM JAPAN TO US - Trading Markets (press release)
... the supervision of clinical trials to the US, where patents for several blockbusters, such as its immunosuppressant drug Prograf, are set to expire. ...
Lifecycle Pharma posts positive data for organ rejection treatment ... - Forbes
'The results are a very important milestone for LCP and demonstrate LCP-Tacro's potential advantages over (competing treatment) Prograf,' Lifecycle Pharma's ...
LifeCycle Pharma Announces Positive Top-line Results of Phase II ... - Business Wire (press release)
LCP-Tacro's improved pharmacokinetics may make this a safer product than Prograf. We believe LCP-Tacro’s once daily profile will provide increased ease of ...
Supreme Court upholds sentence in "MOP-Gate" - La Segunda
... which, on December 4th of last year, condemned the two defendants of the aforementioned crimes in the proceeding also known as MOP-Prograf. ...
iBIO Announces Keynote Speakers for the 2008 iBIO Industry Expo ... - PR-Inside.com (Pressemitteilung)
While in the US, Mr. Hatanaka planned the launch strategy in the United States and Canada for Prograf(R), Astellas' transplant immunosuppressant, ...
iBIO Announces Keynote Speakers for the 2008 iBIO Industry Expo ... - Business Wire (press release)
While in the US, Mr. Hatanaka planned the launch strategy in the United States and Canada for Prograf®, Astellas' transplant immunosuppressant, ...
Astellas Pharma Rises After Increasing Profit Forecast by 33% - Bloomberg
... rose in Tokyo trading after increasing its full-year profit forecast by 33 percent on higher sales of its Prograf immunosuppressant medicine. ...
iBIO Announces Keynote Speakers for the 2008 iBIO Industry Expo ... - Business Wire (press release)
While in the US, Mr. Hatanaka planned the launch strategy in the United States and Canada for Prograf®, Astellas' transplant immunosuppressant, ...
Organ Donor Shortage Remains Obstacle for Would-Be Transplant ... - PR Newswire (press release)
Medicines such as Astella's Prograf and Roche's CellCept have reduced incidence of acute organ rejection and made transplantation a viable option in more ...
Japan's Astellas Pharma April-Dec net profit up 52 pct, lifts FY ... - Trading Markets (press release)
The drug maker said sales of its tacrolimus family of drug products, which includes Prograf, were particularly strong. Net profit rose to 161.2 billion yen ...
Prograf RSS Feed